BAYER AG

🇩🇪Germany

Country: 🇩🇪Germany

Ownership: Public

Established: 1863-08-01

Employees: 99.7K

Market Cap: $30.1B

Website: http://www.bayer.com

Clinical Trials

Bioequivalence of Single Dose Extended Release Naproxen Sodium (660 mg) Tablet Versus Naproxen Sodium (220 mg) Tablet Three Times Daily

Phase 1

Completed

Conditions: Pain

Interventions: Drug: Naproxen Sodium ER (BAY117031), 40% HPMC
Drug: Aleve (Naproxen Sodium, BAY117031)
Drug: Naproxen Sodium ER (BAY117031), 20% HPMC
Drug: Naproxen Sodium ER (BAY117031), 30% HPMC

First Posted Date: 2015-09-15

Last Posted Date: 2015-09-15

Lead Sponsor: Bayer

Target Recruit Count: 32

Registration Number: NCT02549469

Epidemiological Study on the Safety of Aspirin in The Health Improvement Network (THIN)

Completed

Conditions: Secondary Prevention
Coronary Heart Disease
Stroke
Ischemic Heart Disease

Interventions: Drug: Acetylsalicylic Acid (Aspirin, BAYE4465)
Drug: Clopidogrel, Oral Anticoagulants, NSAIDs and SSRIs

First Posted Date: 2015-09-15

Last Posted Date: 2018-10-24

Lead Sponsor: Bayer

Target Recruit Count: 398158

Registration Number: NCT02550717

Effect of Concomitant Use of an Antimycotic, an Antibiotic, a Spermicide or Tampons on Pharmacokinetics of Anastrozole and Levonorgestrel Released From Intra-vaginal Ring

Phase 1

Completed

Conditions: Endometriosis

Interventions: Drug: Anastrozole / Levonorgestrel (BAY98-7196)
Other: Tampon
Drug: Gyno-Daktarin
Drug: Sobelin vaginal creme
Drug: Patentex oval

First Posted Date: 2015-09-10

Last Posted Date: 2017-07-24

Lead Sponsor: Bayer

Target Recruit Count: 52

Registration Number: NCT02545452

A Study to Understand the Treatment Patterns in Patients With Pulmonary Arterial Hypertension or Chronic Thromboembolic Pulmonary Hypertension During a Switch of Treatment to Adempas in Real-life Clinical Practice

Completed

Conditions: Hypertension, Pulmonary

Interventions: Drug: Riociguat (Adempas, BAY63-2521)

First Posted Date: 2015-09-10

Last Posted Date: 2017-05-24

Lead Sponsor: Bayer

Target Recruit Count: 125

Registration Number: NCT02545465

Efficacy and Safety of Finerenone in Subjects With Type 2 Diabetes Mellitus and the Clinical Diagnosis of Diabetic Kidney Disease

Phase 3

Completed

Conditions: Diabetic Kidney Disease

Interventions: Drug: Finerenone (BAY94-8862)
Drug: Placebo

First Posted Date: 2015-09-09

Last Posted Date: 2022-04-15

Lead Sponsor: Bayer

Target Recruit Count: 7352

Registration Number: NCT02545049

Efficacy and Safety of Finerenone in Subjects With Type 2 Diabetes Mellitus and Diabetic Kidney Disease

Phase 3

Completed

Conditions: Chronic Kidney Disease

Interventions: Drug: Finerenone (BAY94-8862)
Drug: Placebo

First Posted Date: 2015-09-04

Last Posted Date: 2023-07-24

Lead Sponsor: Bayer

Target Recruit Count: 5734

Registration Number: NCT02540993

Efficacy and Safety of Two Different Aflibercept Regimens in Subjects With Neovascular Age-related Macular Degeneration (nAMD)

Phase 3

Completed

Conditions: Macular Degeneration

Interventions: Drug: Aflibercept (Eylea, VEGF Trap-Eye, BAY86-5321)

First Posted Date: 2015-09-04

Last Posted Date: 2021-06-11

Lead Sponsor: Bayer

Target Recruit Count: 336

Registration Number: NCT02540954

Locations: 🇨🇦
Clinique medicale de l'oeil de l'Estrie, Sherbrooke, Quebec, Canada

Caregiver Burden of Wet Age-related Macular Degeneration (wAMD) in Japan

Completed

Conditions: Wet Macular Degeneration

Interventions: Drug: Aflibercept (Eylea, VEGF Trap-Eye, BAY86-5321)

First Posted Date: 2015-09-04

Last Posted Date: 2017-08-22

Lead Sponsor: Bayer

Target Recruit Count: 72

Registration Number: NCT02541084

Drug Use Investigation of Gadovist.

Completed

Conditions: Magnetic Resonance Imaging
Image Enhancement

Interventions: Drug: Gadobutrol (Gadavist/Gadovist, BAY86-4875)

First Posted Date: 2015-09-04

Last Posted Date: 2023-11-07

Lead Sponsor: Bayer

Target Recruit Count: 3357

Registration Number: NCT02540967

Locations: 🇯🇵
Many Locations, Multiple Locations, Japan

To Describe the Use of Intravitreal Aflibercept and to Describe Follow-up as Well as Treatment Patterns in Patients With Wet Age-related Macular Degeneration (wAMD) or Diabetic Macular Edema (DME) in Routine Clinical Practice in Canada.

Completed

Conditions: Wet Macular Degeneration

Interventions: Drug: Aflibercept (Eylea, VEGF Trap-Eye, BAY86-5321)

First Posted Date: 2015-09-03

Last Posted Date: 2019-02-15

Lead Sponsor: Bayer

Target Recruit Count: 2150

Registration Number: NCT02540369

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy